Padmanee Sharma

71.9k citations

257 papers · 28.5k indexed · 22 hit papers · h-index 63

Impact in

Oncology top 0.01%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
Immunology top 0.05%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer

Papers in

Oncology 204
- Cancer Immunotherapy and Biomarkers 184
- CAR-T cell therapy research 49
Immunology 110
- Immunotherapy and Immune Responses 75
- Immune Cell Function and Interaction 31
- Immune cells in cancer 22

Co-authors: James P. Allison Jennifer A. Wargo Antoni Ribas Siwen Hu‐Lieskovan Sumit K. Subudhi Golnaz Morad Beth A. Helmink Jianjun Gao
Journals: Journal of Clinical Oncology (78 papers)Journal for ImmunoTherapy of Cancer (16 papers)Cancer Immunology Research (12 papers)Blood (12 papers)Annals of Oncology (12 papers)
Partner nations: United States Italy Germany

In The Last Decade

Padmanee Sharma

246 papers receiving 28.1k citations

Hit Papers

15 papers align trajectories log scale

Immune checkpoint therapy—current perspectives and future directions 2023 · 579 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2023 Cell
2021 Cancer Discovery
2021 Cell
2018 Journal of Clinical Investigation
2018 Journal of Clinical Oncology
2018 Clinical Cancer Research
2017 Nature Medicine
2017 Cell
2017 Journal of Clinical Oncology
2017 The Lancet Oncology
2017 Nature
2017 Cell
2016 Cell
2016 The Lancet Oncology
2015 Science
2015 Cell
2014 Cancer Immunology Research
2014 The Journal of Experimental Medicine
2014 Cancer Immunology Research
2011 Nature reviews. Cancer
2010 Clinical Cancer Research
2007 Proceedings of the National Academy of Sciences

Peers

Countries citing papers authored by Padmanee Sharma

Since Specialization

Citations

This map shows the geographic impact of Padmanee Sharma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Padmanee Sharma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Padmanee Sharma more than expected).

Fields of papers citing papers by Padmanee Sharma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Padmanee Sharma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Padmanee Sharma. The network helps show where Padmanee Sharma may publish in the future.

Co-authors

The 25 scholars most cited alongside Padmanee Sharma, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Padmanee Sharma Line = papers co-authored together Padmanee Sharma links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Durvalumab and tremelimumab before surgery in patients with hormone receptor positive, HER2-negative stage II-III breast cancer Oncotarget ·Haven R. Garber, Sreyashi Basu, Sonali Jindal, Zhong He, Khoi Chu, Akshara Singareeka Raghavendra, Clinton Yam, Lumarie Santiago, Beatriz E. Adrada, Padmanee Sharma, Elizabeth A. Mittendorf, Jennifer K. Litton	2024	2
2	Multimodal Spatial Transcriptomic Profiling Elucidates Niche-Specific Dynamics in Medullary and Extramedullary Acute Myeloid Leukemia Blood ·Laurent Giai-Miniet, Mirjam Jaquemoth, Gianluca Tuteri, Andres Quesada, Fatima Zahra Jelloul, J Insel, Sreyashi Basu, Sonali Jindal, 領田中, Alexander J. Lazar, Khalida Wani, Dinler A. Antunes, Patrick K. Reville, Preethi H. Gunaratne, Robert J. Tower, Padmanee Sharma, Attila Korkmaz	2024	0
3	Analyses of PD-L1 and Inflammatory Gene Expression Association with Efficacy of Nivolumab ± Ipilimumab in Gastric Cancer/Gastroesophageal Junction Cancer Clinical Cancer Research ·Ming Lei, Nathan O. Siemers, Dimple Pandya, Han Chang, Teresa Sánchez, Christopher Harbison, Péter M. Szabó, Yelena Y. Janjigian, Patrick A. Ott, Padmanee Sharma, Johanna C. Bendell, T.R. Jeffry Evans, Filippo de Braud, Ian Chau, Zachary Boyd	2021	57
4	Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275 Clinical Cancer Research ·Matthew D. Galsky, Abdel Saci, Péter M. Szabó, G. Celine Han, Gary D. Grossfeld, Sandra Collette, Arlene O. Siefker‐Radtke, Andrea Necchi, Padmanee Sharma	2020	83
5	Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: CheckMate 032 Nivolumab 1 mg/kg Plus Ipilimumab 3 mg/kg Expansion Cohort Results Journal of Clinical Oncology ·Padmanee Sharma, Arlene O. Siefker‐Radtke, Filippo de Braud, Umberto Basso, Emiliano Calvo, Petri Bono, Michael A. Morse, Paolo A. Ascierto, José A. López-Martín, Peter Brossart, Kristoffer Staal Rohrberg, Begoña Mellado, Bruce S. Fischer, S. Meadows–Shropshire, Abdel Saci, Margaret K. Callahan, Jonathan E. Rosenberg	2019	178
6	Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner Cancer Immunology Research ·Lewis Z. Shi, Sangeeta Goswami, Tihui Fu, Baoxiang Guan, Jianfeng Chen, Liangwen Xiong, Jan Zhang, Derek Ng Tang, Xuejun Zhang, Luis M. Vence, Jorge Blando, James P. Allison, Bao F. Hong, Jianjun Gao, Padmanee Sharma	2019	35
7	Characterization and Comparison of GITR Expression in Solid Tumors Clinical Cancer Research ·Luis M. Vence, Samantha Bucktrout, Irina Fernandez Curbelo, Jorge Blando, Patrizia Di Giacomo, 政之吉田, John Lin, Morten RASMUSSEN, Edward Pascua, Tao Sai, Javier Chaparro‐Riggers, Sumit K. Subudhi, Jorge Scutti, Htet Kyi Wynn, Hao Zhao, Shalini S. Yadav, Anirban Maitra, Ignacio I. Wistuba, James P. Allison, Padmanee Sharma	2019	38
8	Efficacy and Tolerability of Tremelimumab in Locally Advanced or Metastatic Urothelial Carcinoma Patients Who Have Failed First-Line Platinum-Based Chemotherapy Clinical Cancer Research ·Padmanee Sharma, Joohyuk Sohn, Sang Joon Shin, Do‐Youn Oh, Bhumsuk Keam, Hyo Jin Lee, Bidyut Hazarika, Ewa Kalinka‐Warzocha, Filip De Vos, Makris Dimitris, Salvatore Ferro, Feng Xiao, Paul Baverel, P. Verni, Kobby Asubonteng, Nassim Morsli, Luc Dirix	2019	34
9	Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers Clinical Cancer Research ·Anu Sharma, Sumit K. Subudhi, Jorge Blando, Jorge Scutti, Luis M. Vence, Jennifer A. Wargo, James P. Allison, Antoni Ribas, Padmanee Sharma Hit paper breakdown →	2018	266
10	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study Journal of Clinical Oncology ·Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, Brian I. Rini, David F. McDermott, Lionel D. Lewis, Martin H. Voss, Padmanee Sharma, Sumanta K. Pal, Albiruni R. Abdul Razak, Christian Kollmannsberger, Daniel Y.C. Heng, Jennifer L. Spratlin, M. Brent McHenry, Asim Amin Hit paper breakdown →	2017	348
11	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells Clinical Cancer Research ·Chad Tang, James W. Welsh, Patricia M. de Groot, Erminia Massarelli, Joe Y. Chang, Kenneth R. Hess, Sreyashi Basu, Michael A. Curran, Maria E. Cabanillas, Vivek Subbiah, Siqing Fu, Apostolia M. Tsimberidou, Daniel D. Karp, Daniel R. Gomez, Adi Diab, Ritsuko Komaki, John V. Heymach, Padmanee Sharma, Aung Naing, David S. Hong	2016	251
12	ICOS Promotes the Function of CD4+ Effector T Cells during Anti-OX40–Mediated Tumor Rejection Cancer Research ·Todd C. Metzger, Hua Long, Shobha Potluri, Thomas Pertel, Samantha L. Bailey-Bucktrout, John Lin, Tihui Fu, Padmanee Sharma, James P. Allison, 조홍하	2016	49
13	PD-L1 Expression in Triple-Negative Breast Cancer Cancer Immunology Research ·Elizabeth A. Mittendorf, Anne V. Philips, Funda Meric‐Bernstam, Na Qiao, Yun Wu, Susan M. Harrington, Xiaoping Su, Ying Wang, Ana M. González-Angulo, Argun Akçakanat, Akhil Chawla, Michael A. Curran, Patrick Hwu, Padmanee Sharma, Jennifer K. Litton, Jeffrey J. Molldrem, Gheath Alatrash Hit paper breakdown →	2014	1065
14	CD4 T Cells Require ICOS-Mediated PI3K Signaling to Increase T-Bet Expression in the Setting of Anti-CTLA-4 Therapy Cancer Immunology Research ·Hong Chen, Tihui Fu, Woong‐Kyung Suh, Dimitra Tsavachidou, Sijin Wen, Jianjun Gao, Derek Ng Tang, Qiuming He, Jingjing Sun, Padmanee Sharma	2013	44
15	Increased Frequency of ICOS+ CD4 T Cells as a Pharmacodynamic Biomarker for Anti-CTLA-4 Therapy Cancer Immunology Research ·Derek Ng Tang, Yu Shen, Jingjing Sun, Sijin Wen, Jedd D. Wolchok, Jianda Yuan, James P. Allison, Padmanee Sharma	2013	146
16	The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy Cancer Research ·Tihui Fu, Qiuming He, Padmanee Sharma	2011	193
17	Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial Clinical Cancer Research ·Bradley Curtis Carthon, Jedd D. Wolchok, Jianda Yuan, Ashish M. Kamat, Derek S. Ng Tang, Jingjing Sun, Geoffrey Y. Ku, Patricia Troncoso, Christopher J. Logothetis, James P. Allison, Padmanee Sharma Hit paper breakdown →	2010	358
18	NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells Clinical Cancer Research ·Sacha Gnjatic, Nasser K. Altorki, Derek Ng Tang, Shi‐Ming Tu, Vikas Kundra, Gerd Ritter, Lloyd J. Old, Christopher J. Logothetis, Padmanee Sharma	2009	58
19	CTLA-4 blockade increases IFNγ-producing CD4 ⁺ ICOS ^hi cells to shift the ratio of effector to regulatory T cells in cancer patients Proceedings of the National Academy of Sciences ·Chrysoula I. Liakou, Ashish M. Kamat, Derek Ng Tang, Hong Chen, Jingjing Sun, Patricia Troncoso, Christopher J. Logothetis, Padmanee Sharma	2008	428
20	Cancer-Testis Antigens: Expression and Correlation with Survival in Human Urothelial Carcinoma Clinical Cancer Research ·Padmanee Sharma, Yu Shen, Sijin Wen, Dean F. Bajorin, Victor E. Reuter, Lloyd J. Old, Achim A. Jungbluth	2006	75

About Padmanee Sharma

Padmanee Sharma is a scholar working on Oncology, Immunology, Pulmonary and Respiratory Medicine, Surgery and Cancer Research, having authored 257 papers that have together received 28.5k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (184 papers), Immunotherapy and Immune Responses (75 papers), Bladder and Urothelial Cancer Treatments (57 papers), CAR-T cell therapy research (49 papers), Immune Cell Function and Interaction (31 papers), Renal cell carcinoma treatment (30 papers), Immune cells in cancer (22 papers) and Cancer Genomics and Diagnostics (18 papers). The work is most often cited by research in Oncology (20.0k citations), Immunology (13.9k citations), Cancer Research (2.9k citations), Pulmonary and Respiratory Medicine (5.8k citations) and Molecular Biology (6.5k citations). Padmanee Sharma has collaborated with scholars based in United States, Italy and Germany. Frequent co-authors include James P. Allison, Jennifer A. Wargo, Antoni Ribas, Siwen Hu‐Lieskovan, Sumit K. Subudhi, Golnaz Morad, Beth A. Helmink, Jianjun Gao, Jedd D. Wolchok and Sangeeta Goswami. Their work appears in journals such as Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Cancer Immunology Research, Blood and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact